Artelo Biosciences (ARTL)
(Delayed Data from NSDQ)
$1.33 USD
0.00 (0.00%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.38 +0.05 (3.76%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARTL 1.33 0.00(0.00%)
Will ARTL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ARTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARTL
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study
ARTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARTL
UK dividends calendar
UK dividends calendar
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
UK dividends calendar
UK dividends calendar - next 7 days